What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for Sandoz Group AG (
) from 2023 to Apr 24 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sandoz Group AG stock (SDZNY) PE ratio as of Apr 24 2025 is 9999.
More Details
Sandoz Group AG (SDZNY) PE Ratio (TTM) Chart
Sandoz Group AG (SDZNY) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 390
- 1
- 2
- 3
- 4
- 5
| Sandoz Group AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2025-04-24 | At Loss | 2025-02-19 | At Loss |
| 2025-04-23 | At Loss | 2025-02-18 | At Loss |
| 2025-04-22 | At Loss | 2025-02-14 | At Loss |
| 2025-04-21 | At Loss | 2025-02-13 | At Loss |
| 2025-04-17 | At Loss | 2025-02-12 | At Loss |
| 2025-04-16 | At Loss | 2025-02-11 | At Loss |
| 2025-04-15 | At Loss | 2025-02-10 | At Loss |
| 2025-04-14 | At Loss | 2025-02-07 | At Loss |
| 2025-04-11 | At Loss | 2025-02-06 | At Loss |
| 2025-04-10 | At Loss | 2025-02-05 | At Loss |
| 2025-04-09 | At Loss | 2025-02-04 | At Loss |
| 2025-04-08 | At Loss | 2025-02-03 | At Loss |
| 2025-04-07 | At Loss | 2025-01-31 | At Loss |
| 2025-04-04 | At Loss | 2025-01-30 | At Loss |
| 2025-04-03 | At Loss | 2025-01-29 | At Loss |
| 2025-04-02 | At Loss | 2025-01-28 | At Loss |
| 2025-04-01 | At Loss | 2025-01-27 | At Loss |
| 2025-03-31 | At Loss | 2025-01-24 | At Loss |
| 2025-03-28 | At Loss | 2025-01-23 | At Loss |
| 2025-03-27 | At Loss | 2025-01-22 | At Loss |
| 2025-03-26 | At Loss | 2025-01-21 | At Loss |
| 2025-03-25 | At Loss | 2025-01-17 | At Loss |
| 2025-03-24 | At Loss | 2025-01-16 | At Loss |
| 2025-03-21 | At Loss | 2025-01-15 | At Loss |
| 2025-03-20 | At Loss | 2025-01-14 | At Loss |
| 2025-03-19 | At Loss | 2025-01-13 | At Loss |
| 2025-03-18 | At Loss | 2025-01-10 | At Loss |
| 2025-03-17 | At Loss | 2025-01-08 | At Loss |
| 2025-03-14 | At Loss | 2025-01-07 | At Loss |
| 2025-03-13 | At Loss | 2025-01-06 | At Loss |
| 2025-03-12 | At Loss | 2025-01-03 | At Loss |
| 2025-03-11 | At Loss | 2025-01-02 | At Loss |
| 2025-03-10 | At Loss | 2024-12-31 | At Loss |
| 2025-03-07 | At Loss | 2024-12-30 | At Loss |
| 2025-03-06 | At Loss | 2024-12-27 | At Loss |
| 2025-03-05 | At Loss | 2024-12-26 | At Loss |
| 2025-03-04 | At Loss | 2024-12-24 | At Loss |
| 2025-03-03 | At Loss | 2024-12-23 | At Loss |
| 2025-02-28 | At Loss | 2024-12-20 | At Loss |
| 2025-02-27 | At Loss | 2024-12-19 | At Loss |
| 2025-02-26 | At Loss | 2024-12-18 | At Loss |
| 2025-02-25 | At Loss | 2024-12-17 | At Loss |
| 2025-02-24 | At Loss | 2024-12-16 | At Loss |
| 2025-02-21 | At Loss | 2024-12-13 | At Loss |
| 2025-02-20 | At Loss | 2024-12-12 | At Loss |
Sandoz Group AG (SDZNY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sandoz Group AG
ISIN : US7999261008
Share Class Description:
SDZNY: ADRCompare
Compare
Traded in other countries / regions
SDZ.SwitzerlandSDZz.UKSDZNY.USAD8Y0.Germany IPO Date
2023-10-04Description
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers